Veracyte, Inc. filings document the regulatory record for a Nasdaq-listed cancer diagnostics company with a portfolio that includes Decipher, Afirma, Prosigna, and bladder cancer diagnostics. The company’s Form 8-K reports primarily cover operating and financial results, preliminary financial and testing-volume estimates, and material corporate events.
Veracyte’s proxy and governance filings disclose shareholder voting matters, board and executive compensation practices, equity award information, and governance procedures. Other material-event filings address officer appointments, compensatory arrangements, capital-structure disclosures, and formal exhibits tied to financial reporting and corporate actions.
Veracyte, Inc. (VCYT) notice reports a proposed sale of 7,667 shares of common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $234,763.54 and an approximate sale date of 09/04/2025. The filing shows the shares were acquired as Restricted Stock Units from the issuer on 09/02/2025 and payment/vesting is recorded as 09/02/2025. The issuer's total shares outstanding is listed as 78,671,588. The filer reports no securities sold by the same person in the past three months. The notice includes the required representation that the seller does not possess any undisclosed material adverse information regarding the issuer.
This Schedule 13G/A shows Artisan Partners entities beneficially own 6,321,775 shares of Veracyte common stock, equal to 8.1% of the class based on 78,314,611 shares outstanding. The reported position reflects shared voting power of 5,220,102 and shared dispositive power over the full 6,321,775 shares, with no sole voting or dispositive power asserted. The filing states the shares are held for discretionary clients of the adviser and were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control. The document names the reporting entities within the Artisan Partners group.
Veracyte Director Karin Eastham received a grant of 9,321 restricted stock units (RSUs) on June 18, 2025, as reported in this Form 4 filing. The RSUs were awarded at $0 cost and will vest in full on either:
- The first anniversary of the grant date (June 18, 2026), or
- Immediately prior to Veracyte's next annual stockholder meeting, whichever comes first
- Additionally, full vesting occurs upon any change in control of the company
Following this transaction, Eastham now beneficially owns 23,228 shares of Veracyte common stock directly. This equity grant appears to be part of the company's director compensation program. The filing was signed by Jonathan Wygant as attorney-in-fact on June 23, 2025.
Veracyte Director Evan Jones received a grant of 9,321 restricted stock units (RSUs) on June 18, 2025. Following this transaction, Jones beneficially owns a total of 43,664 shares directly.
Key terms of the RSU grant:
- RSUs vest in full on the first anniversary of the grant date
- Alternative vesting occurs immediately prior to the company's next annual stockholder meeting, if earlier
- Accelerated vesting provision triggers upon a change in control
- Grant price: $0
The Form 4 was filed on June 23, 2025, within the required reporting window. The transaction was executed under transaction code 'A' indicating an acquisition of securities. This equity grant appears to be part of the company's director compensation program.
Veracyte Director Robert S. Epstein received a grant of 9,321 restricted stock units (RSUs) on June 18, 2025. Following this transaction, Epstein's direct ownership increased to 73,919 shares.
Key terms of the RSU award:
- Vesting occurs in full on the first anniversary of the grant date
- Alternative vesting trigger: immediately prior to the company's next annual meeting of stockholders, if earlier
- Accelerated vesting provision in the event of a change in control
- Grant price: $0
The Form 4 was filed on June 23, 2025, within the required reporting window. The transaction was executed under transaction code 'A' indicating an acquisition of securities. This equity grant appears to be part of Veracyte's director compensation program.
Form 4 filing for Veracyte, Inc. (VCYT) discloses that director Eliav Barr received 9,321 restricted stock units (RSUs) on 18-Jun-2025. The grant price is shown as $0 because RSUs are awarded, not purchased. After the award, Barr’s direct ownership rises to 51,189 common shares.
The RSUs vest 100 % on the first anniversary of the grant or immediately before the next annual shareholder meeting, whichever occurs first. Full vesting also accelerates upon a change-in-control event. No derivative transactions were reported, and no sales occurred.
This filing signals routine board compensation rather than an open-market purchase. While it incrementally increases insider alignment with shareholders, the share count is small and has minimal dilution impact for Veracyte’s ~72 million outstanding shares (figure not in filing). Investors typically view RSU awards as neutral to slightly positive, given the absence of cash outlay and the long-term incentive structure.